

REGISTERED NUMBER: 03575079 (England and Wales)

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**REPORT OF THE DIRECTORS AND**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31ST MARCH 2017**

SATURDAY



\*A6C6043C\*

A16

05/08/2017

#168

COMPANIES HOUSE

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2017**

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Report of the Directors and Trustees</b>	<b>2</b>
<b>Statement of Financial Activities</b>	<b>4</b>
<b>Notes to the Statement of Financial Activities</b>	<b>5</b>
<b>Balance Sheet</b>	<b>6</b>
<b>Notes to the Financial Statements</b>	<b>7</b>
<b>Independent Examiner's Report</b>	<b>12</b>

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**COMPANY INFORMATION  
FOR THE YEAR ENDED 31ST MARCH 2017**

**DIRECTORS:**

C R Crosdale  
D McIntosh  
Mrs D McIntosh  
Dr D Kalra  
Miss M Townsend  
Miss C Goodin  
L Bell

**SECRETARY:**

S Herian

**REGISTERED OFFICE:**

Paycare House  
1<sup>st</sup> Floor  
George Street  
Wolverhampton  
WV2 4DX

**REGISTERED NUMBER:**

03575079 (England and Wales)

**REGISTERED CHARITY  
NUMBER:**

1077687

**ACCOUNTANTS:**

Seagrave French LLP  
13-15 Regent Street  
Nottingham  
NG1 5BS

**BANKERS:**

Lloyds Bank Plc  
37 Queen Square  
Wolverhampton  
WV1 1TL

**SOLICITORS:**

Wall James Chappell  
15-23 Hagley Road  
Stourbridge  
DY8 1QW

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**REPORT OF THE DIRECTORS AND TRUSTEES  
FOR THE YEAR ENDED 31ST MARCH 2017**

The directors, who are also trustees of the charity, present their report with the financial statements of the company for the year ended 31st March 2017. The directors have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements.

**PRINCIPAL ACTIVITIES**

The principal charitable activities of the company in the year under review were those to provide relief of poverty, sickness and distress, and enhancement of life, to those affected by the disorders Sickle Cell Disease and Thalassaemia, living within the West Midlands and surrounding areas. Those so affected are predominantly from African, Caribbean, Mediterranean and Asian communities. In 2016 the charity had expanded its activities to include working with families with complex and multiple needs, in order to promote, strengthen and improve their life chances.

**DIRECTORS AND TRUSTEES**

The directors and trustees during the year under review were:

C R Crosdale  
D McIntosh  
Mrs D McIntosh  
Dr D Kalra  
Miss M Townsend  
Miss C Goodin  
L Bell

**COMPANY STATUS**

The company is limited by guarantee and is a registered charity (Registered No 1077687)

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

**OBJECTS AND REVIEW OF THE COMPANY**

The report sets out activities and achievements of the charity for 2016/2017.

The organisation was formed in September 1990, and founded as a charity in 1996. The objects of the charity allow the trustees to develop comprehensively and consistently high quality services for users, their carers, families and professionals who interact with them, within the Wolverhampton area.

The Trustees support a number of activities in pursuant of its objects. These are as follows:

- To offer counselling and screening to those individuals affected by Sickle Cell or Thalassaemia.
- To provide advice, support and guidance to affected individuals.
- To increase awareness by developing educational materials and promotion of raising awareness activities.
- To support both universal and voluntary screening programmes.
- To develop robust community development activities to promote and support the affected communities.

The Trustees meet every three months to review overall performance of the charity and to give strategic guidance.

The directors/trustees review, and consider, the charitable company's reserves in the context of risks and funding. In setting a reserves policy the directors aim to establish reasonable but not absolute protection against risks and to balance this with the need to deploy resources in pursuit of the company's charitable objectives. Reserves are intended to:

- 1) Provide protection for most fluctuations in income and expenditure
- 2) Fund future investment needs and non-recurrent premises costs

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**REPORT OF THE DIRECTORS AND TRUSTEES - continued  
FOR THE YEAR ENDED 31ST MARCH 2017**

Over the past two years the organization has seen fluctuation in its income. This reflects the very challenging times that we are operating in generating income from past sources. To this end we have begun not only to diversify and look at other opportunities which can make a contribution to our overheads, but also see where savings can be made to these overheads. The Trustees will continue to regularly review the finances of the charity and despite the difficulties in the past year which saw an increase in our income and a surplus being realized we are therefore pleased that a satisfactory independent accountant's examination has been achieved.

Overall, a range of six to nine months of expenditure plus redundancy costs of £25,000 has been adopted as a reserves target. Reserves at the end of the financial year were £151,792 (2016: £127,667). The Trustees are aware that the funds are lower than the current reserves policy and expect to accumulate additional free reserves through annual operating surpluses or unrestricted donations.

Due to the recent actuarial valuation which shows a current liability of £134,000, as with previous years, the Trustees will continue to be mindful of this liability within its overall reserve policy. In addition discussions have taken place with the pension providers who are content with the provision and approach adopted for managing the liability, as this is manageable in respect to the valuation that is used by them.

The majority of the charitable company's funding is from service level agreements with Local and Health authorities, which normally cover a three year period.

Additional funding is obtained from donations by supporters of the charity, however given the difficult economic climate, like many charities we have seen a reduction in this income, however we are still appreciative of those who continue to collect donations on behalf of the charity. We also recognise that those who make such donations are keen to see our service users directly benefit from their efforts and to this end the Trustees have decided that the majority of these funds will go towards the Hardship Fund established by the charity. Currently a provision of £1,000 has been set aside and will be drawn down within each year's expenditure depending upon individuals identified to receive such support.

The charity has invested surplus funds with objective to generate funds through capital growth. The funds are managed by RBS Fund Managers and are monitored by the Finance Sub Committee with regular reports to the Board. A cautious approach has been taken to risk over the period to reflect the volatility in the market that can occur. In the coming year Trustees will review its investment portfolio in light of the organisation operational requirements.

The Trustees regularly review the finances of the charity and are pleased that a satisfactory independent accountant's examination has been achieved.

**PUBLIC BENEFIT**

All of the charity's activities are aimed at supporting local individuals affected by Sickle Cell or Thalassaemia.

In developing activities and delivering services, the directors have taken account of the guidance published by the Charity Commission on public benefit.


**DEFINED BENEFIT PENSION SCHEME**

A full actuarial valuation was carried out as at 31 March 2016, the results of which are shown in note 9 of the financial statements. The trustees have decided not to have an updated projection valuation of the scheme for this year, due to the cost burden of doing so.

**RISK MANAGEMENT**

The trustees have considered the major risks the charity faces. The charity's system of internal controls is designed to provide reasonable but not absolute assurance against misstatement or loss. The trustees are satisfied that the systems in place mitigate the charity's exposure to the major risks.

**ON BEHALF OF THE BOARD:**

  
D. McIntosh - Director/Trustee

Date: 25 July 2017

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31ST MARCH 2017**

	Notes	Unrestricted Funds £	Restricted Funds £	Total Funds 2017 £	Total Funds 2016 £
<b>INCOME FROM:</b>					
Donations		284	-	284	842
Other trading activities		-	-	-	789
Investment income		55	-	55	49
Charitable activities:					
Grants from:					
Wolverhampton Clinical Commissioning Group		-	106,451	106,451	106,451
Dudley Clinical Commissioning Group		-	16,040	16,040	32,080
Walsall Healthcare NHS Trust		-	55,523	55,523	55,523
Wolverhampton CC		-	1,500	1,500	-
Dudley MBC		-	668	668	-
Staffordshire County Council - BRFC		9,193	82,735	91,928	8,058
Children in Need		-	-	-	1,974
Roald Dahl Children's Charity		-	-	-	1,000
<b>TOTAL INCOME</b>		<u>9,532</u>	<u>262,917</u>	<u>272,449</u>	<u>206,766</u>
<b>EXPENDITURE ON:</b>					
Raising funds	1	267	11,420	11,687	10,104
Charitable activities	2	<u>4,021</u>	<u>244,455</u>	<u>248,476</u>	<u>204,149</u>
<b>TOTAL EXPENDITURE</b>		<u>4,288</u>	<u>255,875</u>	<u>260,163</u>	<u>214,253</u>
Net incoming / (expenditure) before gain or loss on investments		5,244	7,042	12,286	(7,487)
Unrealised gain/(loss) on investments		11,839	-	11,839	(1,859)
Balances brought forward as at 1 April 2016		<u>19,333</u>	<u>108,334</u>	<u>127,667</u>	<u>137,013</u>
Balances carried forward as at 31 March 2017		<u>36,416</u>	<u>115,376</u>	<u>151,792</u>	<u>127,667</u>

The notes form part of these financial statements

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**NOTES TO THE STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31ST MARCH 2017**

	Unrestricted Funds £	Restricted Funds £	Total Funds 2017 £	Total Funds 2016 £
<b>1 RAISING FUNDS</b>				
Wages	173	8,478	<b>8,651</b>	6,980
Social Security	14	694	<b>708</b>	423
Pensions	18	876	<b>894</b>	1,050
Repairs & maintenance	6	118	<b>124</b>	117
Telephone	3	159	<b>162</b>	152
Sundry expenses	3	60	<b>63</b>	34
Postage, printing & stationery	6	107	<b>113</b>	125
Rent & service charge	35	658	<b>693</b>	924
Insurance	2	92	<b>94</b>	83
Light & heat	2	84	<b>86</b>	111
Depreciation - office equipment	1	23	<b>24</b>	29
Bank charges	4	71	<b>75</b>	76
	<u>267</u>	<u>11,420</u>	<u><b>11,687</b></u>	<u>10,104</u>
<b>2 CHARITABLE ACTIVITIES</b>				
Wages	1,644	162,732	<b>164,376</b>	132,622
Social Security	269	13,184	<b>13,453</b>	8,044
Pensions	340	16,644	<b>16,984</b>	19,943
Staff training	-	-	<b>-</b>	-
IT development	-	2,160	<b>2,160</b>	2,160
Travelling	413	7,843	<b>8,256</b>	4,592
Repairs & maintenance	118	2,239	<b>2,357</b>	2,222
Social hardship donation	222	-	<b>222</b>	403
Social support	-	-	<b>-</b>	852
Outreach expenses	-	91	<b>91</b>	577
Consultancy service development	-	13,381	<b>13,381</b>	1,773
Subscriptions	258	-	<b>258</b>	258
Telephone	62	3,015	<b>3,077</b>	2,897
Sundry expenses	60	1,132	<b>1,192</b>	645
Postage, printing & stationery	108	2,044	<b>2,152</b>	2,368
Promotions & information	-	10	<b>10</b>	218
Rent & service charge	263	12,907	<b>13,170</b>	17,557
Insurance	36	1,751	<b>1,787</b>	1,582
Light & heat	33	1,607	<b>1,640</b>	2,104
Depreciation - office equipment	22	428	<b>450</b>	542
Support costs:				
Accountancy	108	2,052	<b>2,160</b>	2,160
Professional fees	65	1,235	<b>1,300</b>	630
	<u>4,021</u>	<u>244,455</u>	<u><b>248,476</b></u>	<u>204,149</u>

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**BALANCE SHEET  
31ST MARCH 2017**

		2017	2016
	Notes	£	£
<b>FIXED ASSETS:</b>			
Tangible assets	4	1,043	1,517
<b>CURRENT ASSETS:</b>			
Debtors	5	38,585	2,859
Investments	6	83,757	71,917
Cash at bank and in hand		<u>100,587</u>	<u>119,158</u>
		222,929	193,934
<b>CREDITORS:</b> Amounts falling due within one year	7	<u>10,180</u>	<u>5,784</u>
<b>NET CURRENT ASSETS:</b>		<u>212,749</u>	<u>188,150</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES:</b>		213,792	189,667
<b>CREDITORS:</b> Amounts falling due after more than one year	8	<u>62,000</u>	<u>62,000</u>
<b>NET ASSETS</b>		<u>151,792</u>	<u>127,667</u>
<b>RESERVES:</b>			
Unrestricted Funds		36,416	19,333
Restricted Funds		<u>115,376</u>	<u>108,334</u>
		<u>151,792</u>	<u>127,667</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 25 July 2017 and were signed on its behalf by:

  
D. McIntosh - Director



**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2017**

**1. ACCOUNTING POLICIES**

**Accounting convention**

The financial statements have been prepared under the historical cost convention and in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", the Charities Act 2011, the Companies Act 2006 and the Statement of Recommended Practice: "Accounting and Reporting by Charities" (FRS 102) with the exception of accounting for the deficit on the defined benefit pension scheme, for which provision has been made as set out below and in note 9.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc	- 25% on cost and
	- 15% & 25% on reducing balance

**Pensions**

The company operates a defined benefit pension scheme which provides benefits based on final pensionable pay. The scheme is administered by the West Midlands Metropolitan Authorities Pension Fund, and the assets are held independently of the finances of the company. The most recent actuarial valuation report was at 31 March 2016. The projected valuation deficit in the scheme at 31 March 2016 was £134,000, the Board has considered this situation and feels that because of the age of the work force this deficit can be eliminated over a period of time and currently a total provision of £62,000 has been made to date in these accounts. The valuation has not been updated at 31 March 2017 due to the cost burden of doing so.

**Restricted Funds**

Monies received as grants for particular purposes are held as separate funds and are credited to the Statement of Financial Activities when costs of the particular relevant projects are incurred.

**Donations**

Donations are credited to the Statement of Financial Activities in the period in which they are received.

**Direct Charitable Expenditure**

Direct charitable expenditure includes the direct costs of the charitable activities and related assets. Where such costs relate to more than one functional cost category, they have been split on an estimate of time spent.

**Investments**

Investments are stated at market value at the balance sheet date. The SOFA includes the net gains or losses arising on revaluation throughout the year.

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2017**

**2. STAFF COSTS**

	2017 £	2016 £
Wages and salaries	173,027	139,602
Social security costs	14,161	8,467
Other pension costs	17,878	20,993
	<u>205,066</u>	<u>169,062</u>

The average monthly number of employees during the year was as follows:

	2017	2016
Charitable Workers	<u>6</u>	<u>5</u>

There are no employees who received total emoluments of more than £60,000.

**3. OPERATING PROFIT/(LOSS)**

The operating profit/(loss) is stated after charging:

	2017 £	2016 £
Depreciation - owned assets	<u>474</u>	<u>571</u>
Directors' emoluments and other benefits etc	<u>-</u>	<u>-</u>

**4. TANGIBLE FIXED ASSETS**

	Plant and machinery	Fixtures and fittings	Totals
	£	£	£
<b>COST:</b>			
At 1st April 2016	6,592	11,830	18,422
Additions	-	-	-
Disposals	-	-	-
At 31st March 2017	<u>6,592</u>	<u>11,830</u>	<u>18,422</u>
<b>DEPRECIATION:</b>			
At 1st April 2016	6,126	10,779	16,905
Charge for year	235	239	474
Eliminated on disposals	-	-	-
At 31st March 2017	<u>6,361</u>	<u>11,018</u>	<u>17,379</u>
<b>NET BOOK VALUE:</b>			
At 31st March 2017	<u>231</u>	<u>812</u>	<u>1,043</u>
At 31st March 2016	<u>466</u>	<u>1,051</u>	<u>1,517</u>

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2017**

**5. DEBTORS: AMOUNTS FALLING  
DUE WITHIN ONE YEAR**

	<b>2017</b>	<b>2016</b>
	<b>£</b>	<b>£</b>
Prepayments and accrued income	<u><b>38,585</b></u>	<u><b>2,859</b></u>

**6. CURRENT ASSET INVESTMENTS**

	<b>2017</b>	<b>2016</b>
	<b>£</b>	<b>£</b>
RBS Investment Options ICVC multi manager funds	<u><b>83,757</b></u>	<u><b>71,917</b></u>

**7. CREDITORS: AMOUNTS FALLING  
DUE WITHIN ONE YEAR**

	<b>2017</b>	<b>2016</b>
	<b>£</b>	<b>£</b>
Social security and other tax	<b>5,732</b>	-
Accruals and deferred income	<u><b>4,448</b></u>	<u><b>5,784</b></u>
	<u><b>10,180</b></u>	<u><b>5,784</b></u>

**8. CREDITORS: AMOUNTS FALLING  
DUE AFTER MORE THAN ONE YEAR**

	<b>2017</b>	<b>2016</b>
	<b>£</b>	<b>£</b>
Provision for defined pension scheme deficit (see note 9)	<u><b>62,000</b></u>	<u><b>62,000</b></u>

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2017**

**9. PENSION SCHEME**

	2017 £	2016 £
Value of scheme assets and liabilities		
Market value of assets	381,000	355,000
Present value of scheme liabilities	<u>(515,000)</u>	<u>(607,000)</u>
Pension scheme deficit	<u>(134,000)</u>	<u>(252,000)</u>

The above is based on an actuarial valuation at 31 March 2016. Provision of £62,000 has been made towards the above deficit. The valuation has not been updated at 31 March 2017 due to the cost burden of doing so. New contribution rates have been set with the intention of clearing the above deficit over the next 10 years.

**10. OPERATING LEASE COMMITMENTS**

The following operating lease payments are committed to be paid within one year:

	2017 £	2016 £
Expiring within three years	<u>-</u>	<u>18,000</u>

**11. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Fixed Assets £	Net Current Assets £	Total Net Assets £
Unrestricted Funds	229	36,187	27,223
Restricted Funds	<u>814</u>	<u>114,562</u>	<u>124,569</u>
	<u>1,043</u>	<u>150,749</u>	<u>151,792</u>

**12. SHARE CAPITAL**

The company is limited by guarantee and does not have a Share Capital. In the event of winding up, each member has undertaken to contribute an amount not exceeding £1.

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2017**

**RESTRICTED FUNDS**

<b>Fund</b>	<b>Purpose of Fund</b>	<b>Reason for Restriction</b>
Wolverhampton CCG	Support the antenatal and newborn screening programme and provide counselling and support to those affected	Wolverhampton residents only
Dudley CCG/MBC	Support affected adults and children with long term conditions to manage their condition through various social and community interventions	Dudley residents only
Walsall Healthcare NHS Trust	Support the antenatal and newborn screening programme and provide counselling and support to those affected	Walsall residents only
Children in Need	Support affected young people with social/engagement activities To encourage confidence building and effective management of their condition	Young people living with sickle cell or thalassaemia
Road Dahl Children's Charity	Helps to make life better for seriously ill children in the UK.	Young people living with sickle cell or thalassaemia
Staffordshire County Council	Building resilient families & communities – aims to work with families who have been identified that may benefit from some additional support	Families identified by Staffordshire County Council through their own criteria

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

I report on the accounts of the company for the year ended 31 March 2017 which are set out on pages 2 to 11.

**Respective responsibilities of trustees and examiner**

The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144 (2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

Having satisfied myself that the charity is not subject to an audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act, and
- state whether particular matters have come to my attention.

**Basis of independent examiner's report**


My examination was carried out in accordance with general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.

**Independent examiner's statement**

I refer to the paragraph titled 'Defined Benefit Pension Scheme' in the Trustees Report on page 3. As mentioned in this paragraph the trustees have decided not to have an updated projection valuation of the scheme for this year, due to the cost burden of doing so.

In connection with my examination, and subject to the above, no further matter has come to my attention:

- 1 which gives me reasonable cause to believe that, in any material respect, the requirements:
  - to keep accounting records in accordance with section 386 of the Companies Act 2006, and
  - to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charitieshave not been met; or
- 2 to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Jason Seagrave FCCA  
Seagrave French LLP  
13-15 Regent Street  
Nottingham  
NG1 5BS

Date 1/8/17